Sinusitis Treatment Market Estimated to Cross US$ 4.3 Bn by 2030

The worldwide Sinusitis Treatment market measurement is anticipated to achieve USD 4.3 billion by 2030 and is anticipated to increase at a CAGR of 4.1% from 2021 to 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38529

Sinuses are a connected system of air-filled cavities located in the skull. Sinusitis is an inflammation of the sinus lining caused by bacteria, virus, fungi, and microbes. Bacterial sinusitis is less common than viral sinusitis and requires antibiotics, while viral sinusitis is most common and does not require antibiotics.

Fungal sinusitis is also known as allergic fungal sinusitis and is caused by aspergillosis fungi. Possible symptoms of sinus infection are nasal obstruction, discolored nasal discharge, and facial pain that lasts for seven days or more. Facial pain is a common symptom in sinusitis. A patient could feel pain around the eye, forehead, nose, and root of teeth. There are three primary types of sinusitis: acute sinusitis, sub-acute sinusitis, and chronic sinusitis.

Acute rhinosinusitis is a general disease with global prevalence. The disease is a major burden on health services. Rhinosinusitis is a major health problem globally. It is an infection of the nasal passages and paranasal sinuses.

Primary care physicians usually tend to think of sinusitis as an acute bacterial infection. Hence, antibiotics are prescribed to 92% of patients in the U.K. and 85% to 98% of sinusitis patients in the U.S. In 2003, the number of medical prescriptions for acute bacterial sinusitis was around 7.6 million in Germany. In France, around 7% of all antibiotics are prescribed to treat suspected acute bacterial sinusitis.

The annual cost of treatment in the U.K. is GBP 10 Mn (EUR 14.7 Mn, US$ 20 Mn). In 1996, the total cost of prescription and non‐prescription medications used for the treatment of sinusitis in the U.S. was around US$ 3.39 Bn (EUR 2.5 Bn, GBP 1.7 Bn). Rhinosinusitis accounted for around 12 million to 17 million annual visits to physicians and 12% of antibiotics prescribed to geriatric patients in the U.S., making it one of the 10 most common conditions to be treated in ambulatory practice. Hence, increase in cases of acute rhinosinusitis is projected to fuel the growth of the global sinusitis treatment market.

Report Scope

In terms of treatment, the global sinusitis treatment market has been classified into analgesics, antihistamines, corticosteroids, antibiotics, sulphonamides, quinolones, and surgery. Antibiotics have been split into cephalosporin, penicillin, and macrolide. The surgery segment has been bifurcated into endoscopy and balloon sinusplasty. The antihistamines segment accounted for 32% share of the global market in 2020. The segment is anticipated to expand at a CAGR of 3.8% from 2021 to 2030. Antihistamines are over-the-counter medication used to relieve cold, sinus, and allergy symptoms. Hence, increase in usage of these drugs boosts the growth of the segment.

Based on disease type, the global sinusitis treatment market has been categorized into acute sinusitis, sub-acute sinusitis, and chronic sinusitis. The acute sinusitis segment accounted for 35% share of the market in 2020. The segment is expected to expand at a CAGR of 4% from 2021 to 2030. Acute sinusitis is generally caused by common cold. Signs and symptoms could include nasal obstruction and congestion, which may block sinuses in patients and prevent drainage of mucus. Hence, rise in cases of common cold & flu increases the incidence of acute sinusitis. This, in turn, propels the global sinusitis treatment market.

In terms of route of administration, the global sinusitis treatment market has been segregated into topical, nasal, oral, and injectable. The oral segment accounted for 60% share of the global market in 2020. The segment is projected to expand at a CAGR of 3.7% from 2021 to 2030. The oral pathway has attracted the most attention due to unique advantages, including sustained and controllable delivery, feasibility for solid formulations, ease of administration, patient compliance, and an intensified immune response in the case of vaccines.

Based on distribution channel, the global sinusitis treatment market has been divided into online pharmacies, retail pharmacies, and hospital pharmacies. The retail pharmacies segment held 44% share of the market in 2020. The segment is likely to gain market share marginally to reach 44.7% by 2030, as drugs are easily available and various brands are offered at reasonable prices at retail pharmacies.

In terms of region, the global sinusitis treatment market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is projected to account for a significant share of the global market because of higher prevalence of sinusitis. According to the Centers for Disease Control and Prevention (CDC), nearly 26.8 million people were diagnosed with sinusitis in the U.S. in 2019. Europe is anticipated to be a key market for sinusitis treatment due to rise in invasive bacterial diseases and innovation in diagnosis of bacterial infections.

The sinusitis treatment market in Asia Pacific is expected to grow at a rapid pace during the forecast period due to increase in bacterial and viral diseases. However, factors, such as lack of knowledge of diagnostic tests and awareness among people about sinusitis is likely to hamper the growth of the market in the region.

Competitive Landscape and Market Share Analysis

The sinusitis treatment market competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, sinusitis treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2017-2020, this study provides the sinusitis treatment sales, revenue and market share for each player covered in this report.

  • Crucial data regarding the major contenders, product portfolio, market remuneration, and production patterns are documented in the report.
  • The report presents the pricing models followed by each company, alongside the gross margins and market share held by each company.

The global sinusitis treatment market is fragmented due to the presence of a large number of leading players. Key players operating in the global market include Sun Pharmaceutical Industries, Inc., Pfizer, Inc., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Fresenius Kabi USA, LLC, Dr. Reddy’s Laboratories, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, Abbott Laboratories, Bayer AG, Eli Lilly and Company, Bristol-Myers Squibb, Merck & Co, Inc., AstraZeneca plc, Amneal Pharmaceuticals LLC, GlaxoSmithKline plc., Aurobindo Pharma, Hikma Pharmaceuticals plc, Wockhardt, and Mylan N.V.

Global Sinusitis Treatment Market: Segmentation

Sinusitis Treatment Market, By Treatment

    • Antihistamines
    • Analgesics
    • Corticosteroids
    • Antibiotics
      • Cephalosporin
      • Penicillin
      • Macrolide
    • Sulphonamides
    • Quinolones
    • Surgery
      • Endoscopy
      • Balloon Sinusplasty

Sinusitis Treatment Market, By Disease Type

    • Acute Sinusitis
    • Sub-acute Sinusitis
    • Chronic Sinusitis

Sinusitis Treatment Market, By Route of Administration

    • Topical
    • Nasal
    • Oral
    • Injectable

Sinusitis Treatment Market, By Distribution Channel

    • Online Pharmacies
    • Retail Pharmacies
    • Hospital Pharmacies

Sinusitis Treatment Market, By Region

    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • GCC Countries
      • South Africa
      • Rest of Middle East & Africa

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38529

Research Methodology

The research methodology adopted by analysts for compiling the global sinusitis treatment market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global sinusitis treatment market.

Table of Contents

Chapter 1.    Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.    Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.    Executive Summary

3.1.  Market Snapshot

Chapter 4.    Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.     Raw Material Procurement Analysis

4.3.2.     Sales and Distribution Channel Analysis

4.3.3.     Downstream Buyer Analysis

Chapter 5.    Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.     Market Drivers

5.1.2.     Market Restraints

5.1.3.     Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.     Bargaining power of suppliers

5.2.2.     Bargaining power of buyers

5.2.3.     Threat of substitute

5.2.4.     Threat of new entrants

5.2.5.     Degree of competition

Chapter 6.    Competitive Landscape

6.1.1.     Company Market Share/Positioning Analysis

6.1.2.     Key Strategies Adopted by Players

6.1.3.     Vendor Landscape

6.1.3.1.          List of Suppliers

6.1.3.2.          List of Buyers

Chapter 7.    Global Sinusitis Treatment Market, By Treatment

7.1.  Sinusitis Treatment Market, by Treatment, 2021-2030

7.1.1.     Antihistamines

7.1.1.1.          Market Revenue and Forecast (2016-2030)

7.1.2.     Analgesics

7.1.2.1.          Market Revenue and Forecast (2016-2030)

7.1.3.     Corticosteroids

7.1.3.1.          Market Revenue and Forecast (2016-2030)

7.1.4.     Antibiotics

7.1.4.1.          Market Revenue and Forecast (2016-2030)

7.1.5.     Sulphonamides

7.1.5.1.          Market Revenue and Forecast (2016-2030)

7.1.6.     Quinolones

7.1.6.1.          Market Revenue and Forecast (2016-2030)

7.1.7.     Surgery

7.1.7.1.          Market Revenue and Forecast (2016-2030)

Chapter 8.    Global Sinusitis Treatment Market, By Disease Type

8.1.  Sinusitis Treatment Market, by Disease Type, 2021-2030

8.1.1.     Acute Sinusitis

8.1.1.1.          Market Revenue and Forecast (2016-2030)

8.1.2.     Sub-acute Sinusitis

8.1.2.1.          Market Revenue and Forecast (2016-2030)

8.1.3.     Chronic Sinusitis

8.1.3.1.          Market Revenue and Forecast (2016-2030)

Chapter 9.    Global Sinusitis Treatment Market, By Route of Administration

9.1.  Sinusitis Treatment Market, by Route of Administration, 2021-2030

9.1.1.     Topical

9.1.1.1.          Market Revenue and Forecast (2016-2030)

9.1.2.     Nasal

9.1.2.1.          Market Revenue and Forecast (2016-2030)

9.1.3.     Oral

9.1.3.1.          Market Revenue and Forecast (2016-2030)

9.1.4.     Injectable

9.1.4.1.          Market Revenue and Forecast (2016-2030)

Chapter 10.Global Sinusitis Treatment Market, By Distribution Channel

10.1.          Sinusitis Treatment Market, by Distribution Channel, 2021-2030

10.1.1.  Online Pharmacies

10.1.1.1.       Market Revenue and Forecast (2016-2030)

10.1.2.  Retail Pharmacies

10.1.2.1.       Market Revenue and Forecast (2016-2030)

10.1.3.  Hospital Pharmacies

10.1.3.1.       Market Revenue and Forecast (2016-2030)

Chapter 11.Global Sinusitis Treatment Market, Regional Estimates and Trend Forecast

11.1.          North America

11.1.1.  Market Revenue and Forecast, by Treatment (2016-2030)

11.1.2.  Market Revenue and Forecast, by Disease Type (2016-2030)

11.1.3.  Market Revenue and Forecast, by Route of Administration (2016-2030)

11.1.4.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

11.1.5.  U.S.

11.1.5.1.       Market Revenue and Forecast, by Treatment (2016-2030)

11.1.5.2.       Market Revenue and Forecast, by Disease Type (2016-2030)

11.1.5.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

11.1.5.4.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

11.1.6.  Rest of North America

11.1.6.1.       Market Revenue and Forecast, by Treatment (2016-2030)

11.1.6.2.       Market Revenue and Forecast, by Disease Type (2016-2030)

11.1.6.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

11.1.6.4.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

11.2.          Europe

11.2.1.  Market Revenue and Forecast, by Treatment (2016-2030)

11.2.2.  Market Revenue and Forecast, by Disease Type (2016-2030)

11.2.3.  Market Revenue and Forecast, by Route of Administration (2016-2030)

11.2.4.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

11.2.5.  UK

11.2.5.1.       Market Revenue and Forecast, by Treatment (2016-2030)

11.2.5.2.       Market Revenue and Forecast, by Disease Type (2016-2030)

11.2.5.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

11.2.5.4.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

11.2.6.  Germany

11.2.6.1.       Market Revenue and Forecast, by Treatment (2016-2030)

11.2.6.2.       Market Revenue and Forecast, by Disease Type (2016-2030)

11.2.6.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

11.2.6.4.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

11.2.7.  France

11.2.7.1.       Market Revenue and Forecast, by Treatment (2016-2030)

11.2.7.2.       Market Revenue and Forecast, by Disease Type (2016-2030)

11.2.7.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

11.2.7.4.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

11.2.8.  Rest of Europe

11.2.8.1.       Market Revenue and Forecast, by Treatment (2016-2030)

11.2.8.2.       Market Revenue and Forecast, by Disease Type (2016-2030)

11.2.8.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

11.2.8.4.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

11.3.          APAC

11.3.1.  Market Revenue and Forecast, by Treatment (2016-2030)

11.3.2.  Market Revenue and Forecast, by Disease Type (2016-2030)

11.3.3.  Market Revenue and Forecast, by Route of Administration (2016-2030)

11.3.4.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

11.3.5.  India

11.3.5.1.       Market Revenue and Forecast, by Treatment (2016-2030)

11.3.5.2.       Market Revenue and Forecast, by Disease Type (2016-2030)

11.3.5.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

11.3.5.4.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

11.3.6.  China

11.3.6.1.       Market Revenue and Forecast, by Treatment (2016-2030)

11.3.6.2.       Market Revenue and Forecast, by Disease Type (2016-2030)

11.3.6.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

11.3.6.4.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

11.3.7.  Japan

11.3.7.1.       Market Revenue and Forecast, by Treatment (2016-2030)

11.3.7.2.       Market Revenue and Forecast, by Disease Type (2016-2030)

11.3.7.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

11.3.7.4.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

11.3.8.  Rest of APAC

11.3.8.1.       Market Revenue and Forecast, by Treatment (2016-2030)

11.3.8.2.       Market Revenue and Forecast, by Disease Type (2016-2030)

11.3.8.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

11.3.8.4.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

11.4.          MEA

11.4.1.  Market Revenue and Forecast, by Treatment (2016-2030)

11.4.2.  Market Revenue and Forecast, by Disease Type (2016-2030)

11.4.3.  Market Revenue and Forecast, by Route of Administration (2016-2030)

11.4.4.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

11.4.5.  GCC

11.4.5.1.       Market Revenue and Forecast, by Treatment (2016-2030)

11.4.5.2.       Market Revenue and Forecast, by Disease Type (2016-2030)

11.4.5.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

11.4.5.4.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

11.4.6.  North Africa

11.4.6.1.       Market Revenue and Forecast, by Treatment (2016-2030)

11.4.6.2.       Market Revenue and Forecast, by Disease Type (2016-2030)

11.4.6.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

11.4.6.4.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

11.4.7.  South Africa

11.4.7.1.       Market Revenue and Forecast, by Treatment (2016-2030)

11.4.7.2.       Market Revenue and Forecast, by Disease Type (2016-2030)

11.4.7.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

11.4.7.4.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

11.4.8.  Rest of MEA

11.4.8.1.       Market Revenue and Forecast, by Treatment (2016-2030)

11.4.8.2.       Market Revenue and Forecast, by Disease Type (2016-2030)

11.4.8.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

11.4.8.4.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

11.5.          Latin America

11.5.1.  Market Revenue and Forecast, by Treatment (2016-2030)

11.5.2.  Market Revenue and Forecast, by Disease Type (2016-2030)

11.5.3.  Market Revenue and Forecast, by Route of Administration (2016-2030)

11.5.4.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

11.5.5.  Brazil

11.5.5.1.       Market Revenue and Forecast, by Treatment (2016-2030)

11.5.5.2.       Market Revenue and Forecast, by Disease Type (2016-2030)

11.5.5.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

11.5.5.4.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

11.5.6.  Rest of LATAM

11.5.6.1.       Market Revenue and Forecast, by Treatment (2016-2030)

11.5.6.2.       Market Revenue and Forecast, by Disease Type (2016-2030)

11.5.6.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

11.5.6.4.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

Chapter 12.   Company Profiles

12.1.                 Sun Pharmaceutical Industries Inc.

12.1.1.  Company Overview

12.1.2.  Product Offerings

12.1.3.  Financial Performance

12.1.4.  Recent Initiatives

12.2.                 Pfizer Inc.

12.2.1.  Company Overview

12.2.2.  Product Offerings

12.2.3.  Financial Performance

12.2.4.  Recent Initiatives

12.3.                 Janssen Pharmaceuticals Inc.

12.3.1.  Company Overview

12.3.2.  Product Offerings

12.3.3.  Financial Performance

12.3.4.  Recent Initiatives

12.4.                 Dr. Reddy’s Laboratories Inc.

12.4.1.  Company Overview

12.4.2.  Product Offerings

12.4.3.  Financial Performance

12.4.4.  Recent Initiatives

12.5.                 Novartis AG

12.5.1.  Company Overview

12.5.2.  Product Offerings

12.5.3.  Financial Performance

12.5.4.  Recent Initiatives

12.6.                 Teva Pharmaceutical Industries Ltd.

12.6.1.  Company Overview

12.6.2.  Product Offerings

12.6.3.  Financial Performance

12.6.4.  Recent Initiatives

12.7.                 Sanofi

12.7.1.  Company Overview

12.7.2.  Product Offerings

12.7.3.  Financial Performance

12.7.4.  Recent Initiatives

12.8.                 Abbott Laboratories

12.8.1.  Company Overview

12.8.2.  Product Offerings

12.8.3.  Financial Performance

12.8.4.  Recent Initiatives

12.9.                 Bayer AG

12.9.1.  Company Overview

12.9.2.  Product Offerings

12.9.3.  Financial Performance

12.9.4.  Recent Initiatives

12.10.              Eli Lilly and Company

12.10.1.                   Company Overview

12.10.2.                   Product Offerings

12.10.3.                   Financial Performance

12.10.4.                   Recent Initiatives

12.11.              Bristol-Myers Squibb, Merck & Co, Inc.

12.11.1.                   Company Overview

12.11.2.                   Product Offerings

12.11.3.                   Financial Performance

12.11.4.                   Recent Initiatives

Chapter 13.   Research Methodology

13.1.                 Primary Research

13.2.                 Secondary Research

13.3.                 Assumptions

Chapter 14.   Appendix

14.1.                 About Us

14.2.                 Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38529

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com